Neurotrophic keratopathy: Pros and cons of current treatments

被引:29
|
作者
Di Zazzo, Antonio [1 ]
Coassin, Marco [1 ]
Varacalli, Giuseppe [1 ]
Galvagno, Emanuela [1 ]
De Vincentis, Antonio [2 ]
Bonini, Stefano [1 ]
机构
[1] Univ Campus Biomed, Ophthalmol Complex Operat Unit, I-00128 Rome, Italy
[2] Univ Campus Biomed, Dept Clin Med, Rome, Italy
来源
OCULAR SURFACE | 2019年 / 17卷 / 04期
关键词
Neurotrophic keratopathy; Innovative therapy; Sensitivity; Nerve regeneration; AMNIOTIC MEMBRANE TRANSPLANTATION; PERSISTENT EPITHELIAL DEFECTS; SERUM EYE DROPS; GROWTH-FACTOR-I; AUTOLOGOUS SERUM; SUBSTANCE-P; TOPICAL TREATMENT; PLASMA RICH; EYEDROPS; EFFICACY;
D O I
10.1016/j.jtos.2019.09.002
中图分类号
R77 [眼科学];
学科分类号
100212 ;
摘要
Background: Several therapeutics have been proposed for neurotrophic keratitis, but no direct comparison among different approaches is available. Objective: To compare treatment-related problems and outcomes of both traditional and novel therapeutics for neurotrophic keratopathy, focusing on resolution rate, healing time, and recurrence rate. Data sources: Literature search of published studies between 1980 and 2019 on neurotrophic keratopathy available on PubMed was made without any language constraints but limited to human study participants. Study selection: All published peer-reviewed open, blinded and randomized clinical trials, case series and case reports, divided according to evidence level, were reviewed and resolution rate, healing time, relapses of the disease, and visual outcomes were evaluated. Data extraction and synthesis: Single observer data extraction. Main outcomes and measures: resolution rate, healing time, recurrence rate. Results: Human recombinant Nerve Growth Factor eye drops, Serum Tears and Substance P showed comparable resolution rate in patients with neurotrophic keratopathy. Amniotic membrane transplantation and Nerve Growth Factor eye drops are associated with a faster healing time among available treatments. Nerve Growth Factor eye drops clinical trial are the only study with evidence level 1, hence randomized and controlled. Conclusions and relevance: Several new treatment options are available for patients with neurotrophic keratitis with adequate safety.
引用
收藏
页码:619 / 623
页数:5
相关论文
共 50 条
  • [1] Neurotrophic Keratopathy: Current Perspectives
    Soifer, Matias
    Starr, Christopher E.
    Mousa, Hazem M.
    Savarain, Christian
    Perez, Victor L.
    [J]. CURRENT OPHTHALMOLOGY REPORTS, 2020, 8 (02) : 29 - 35
  • [2] Neurotrophic Keratopathy: Current Perspectives
    Matias Soifer
    Christopher E. Starr
    Hazem M. Mousa
    Christian Savarain
    Victor L. Perez
    [J]. Current Ophthalmology Reports, 2020, 8 : 29 - 35
  • [3] PROS AND CONS OF THE NONSURGICAL TREATMENTS FOR GALLBLADDER STONES
    THISTLE, JL
    [J]. HEPATO-GASTROENTEROLOGY, 1989, 36 (05) : 327 - 329
  • [4] Robotic exoskeletons: The current pros and cons
    Gorgey, Ashraf S.
    [J]. WORLD JOURNAL OF ORTHOPEDICS, 2018, 9 (09): : 112 - 119
  • [5] The Pros and Cons of the PROs
    Thoma, Achilleas
    Eaves, Felmont F., III
    [J]. AESTHETIC SURGERY JOURNAL, 2018, 38 (03) : 343 - 345
  • [6] Pros and cons of current brain tumor imaging
    Ellingson, Benjamin M.
    Wen, Patrick Y.
    van den Bent, Martin J.
    Cloughesy, Timothy F.
    [J]. NEURO-ONCOLOGY, 2014, 16 : 2 - 11
  • [7] Neurotrophic keratopathy: current challenges and future prospects
    NaPier, Erin
    Camacho, Matthew
    McDevitt, Timothy F.
    Sweeney, Adam R.
    [J]. ANNALS OF MEDICINE, 2022, 54 (01) : 666 - 673
  • [8] Current and experimental treatment approaches for neurotrophic keratopathy
    Alder, J.
    Mertsch, S.
    Menzel-Severing, J.
    Geerling, G.
    [J]. OPHTHALMOLOGE, 2019, 116 (02): : 127 - 137
  • [9] PSYCHOSIS AND SLEEP DEPRIVATION: PROS AND CONS OF EXISTING AND NEW TREATMENTS
    Waters, Flavie
    Chiu, Vivian
    Lin, Ashleigh
    [J]. SCHIZOPHRENIA BULLETIN, 2015, 41 : S130 - S131
  • [10] Pros and cons of treatments and studies of recurrent febrile seizures - Reply
    Rantala, H
    Tarkka, R
    Uhari, M
    [J]. JOURNAL OF PEDIATRICS, 1998, 133 (05): : 715 - 715